Literature DB >> 12081610

Changing scenario of hepatitis A virus and hepatitis E virus exposure among the primitive tribes of Andaman and Nicobar Islands, India over the 10-year period 1989-99.

M V Murhekar1, S C Sehgal, K M Murhekar, S P Padbhidri, S D Chitambar, V A Arankalle.   

Abstract

The Andaman and Nicobar Islands, Union Territory of India, are home to six primitive tribes. Studies carried out earlier among these tribes revealed very high rates of hepatitis B infection. We have now studied hepatitis A and E infection among them. A total of 951 serum samples were collected from four accessible tribes (Nicobarese, Shompens, Onges and Great Andamanese) and tested for antibodies against hepatitis A and E viruses. In addition, 240 serum samples collected a decade earlier from age-stratified Nicobarese were also screened. Hepatitis A virus (HAV) infection was found to be highly endemic among all the tribes, whereas hepatitis E virus (HEV) infection was common among the Nicobarese and Shompens. The age group-wise prevalence of these infections among the Nicobarese showed different patterns, HAV prevalence rising significantly from those aged 10 years and thereafter reaching a plateau, whereas HEV prevalence was found to be more evenly distributed over all age groups, but rising somewhat after 30 years of age. Over the last decade, the prevalence of HAV among the Nicobarese has declined slightly, particularly in those aged 10 years or less whereas HEV infection has more than doubled over all age ranges. Different HEV prevalence observed among the tribes could not be attributed to differences in sanitation or water supply. This fact and the different age-wise patterns of HAV and HEV prevalences is suggestive of different modes of transmission of HEV that are not shared. The highest rates for HEV were among those tribes which reared pigs suggesting that pigs might serve as reservoir of HEV. Further studies are needed, however, to validate these findings.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12081610     DOI: 10.1046/j.1365-2893.2002.00355.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  7 in total

1.  Community-based cross-sectional seroprevalence study of hepatitis A in Bangladesh.

Authors:  Samir K Saha; Setarunnahar Saha; Salim Shakur; Mohammed Hanif; Md Ahsan Habib; Sanjoy K Datta; Hans L Bock
Journal:  World J Gastroenterol       Date:  2009-10-21       Impact factor: 5.742

2.  Water borne hepatitis a and hepatitis e in malwa region of punjab, India.

Authors:  Deepak Arora; Neerja Jindal; Ravinder K Shukla; Renu Bansal
Journal:  J Clin Diagn Res       Date:  2013-10-05

3.  Seroprevalence study of hepatitis A virus in Fars province, southern Iran.

Authors:  Seyed Alireza Taghavi; Mohammad Kazem Hosseini Asl; Mozaffar Talebzadeh; Ahad Eshraghian
Journal:  Hepat Mon       Date:  2011-04-01       Impact factor: 0.660

Review 4.  Light and Darkness: Prevalence of Hepatitis E Virus Infection among the General Population.

Authors:  José-Manuel Echevarría
Journal:  Scientifica (Cairo)       Date:  2014-02-10

5.  Hepatitis A and E seroprevalence and associated risk factors: a community-based cross-sectional survey in rural Amazonia.

Authors:  Claudia Lamarca Vitral; Mônica da Silva-Nunes; Marcelo Alves Pinto; Jaqueline Mendes de Oliveira; Ana Maria Coimbra Gaspar; Rebeca Cristina Costa Pereira; Marcelo Urbano Ferreira
Journal:  BMC Infect Dis       Date:  2014-08-23       Impact factor: 3.090

6.  Seroprevalence of hepatitis A and hepatitis E in patients at a teaching hospital of northern India over a period of 8 years.

Authors:  Yashik Bansal; Nidhi Singla; Karan Garg; Geetanjali Sharma; Meenakshi Gill; Jagdish Chander
Journal:  J Family Med Prim Care       Date:  2022-02-16

7.  Setting a Course for Preventing Hepatitis E in Low and Lower-Middle-Income Countries: A Systematic Review of Burden and Risk Factors.

Authors:  Aybüke Koyuncu; Daniel Mapemba; Iza Ciglenecki; Emily S Gurley; Andrew S Azman
Journal:  Open Forum Infect Dis       Date:  2021-04-13       Impact factor: 3.835

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.